The Colorectal Cancer Partnering 2007-2012 report provides understanding and access to the colorectal cancer partnering deals and agreements entered into by the worlds leading healthcare companies.
- Trends in colorectal cancer partnering deals
- Top colorectal cancer deals by value
- Deals listed by company A-Z, industry sector, stage of development, technology type
The Colorectal Cancer Partnering 2007-2012 provides understanding and access to the colorectal cancer partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of colorectal cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors colorectal cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner?s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered ? contract documents provide this insight where press releases do not.
This data driven report contains over 150 links to online copies of actual colorectal cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner?s flexibility on a wide range of important issues, many of which will have a significant impact on each party?s ability to derive value from the deal.
The initial chapters of this report provide an orientation of colorectal cancer partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in colorectal cancer partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading colorectal cancer deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of colorectal cancer partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of colorectal cancer technologies and products.
Report scope
Colorectal Cancer Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to colorectal cancer trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
- Trends in colorectal cancer dealmaking in the biopharma industry since 2007
- Access to summary headline, upfront, milestone and royalty data
- Access to over 150 colorectal cancer contract documents
- The leading colorectal cancer deals by value since 2007
In Colorectal Cancer Partnering 2007-2012, the available deals are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Colorectal Cancer Partnering 2007-2012 provides the reader with the following key benefits:
- In-depth understanding of colorectal cancer deal trends since 2007
- Access to summary headline, upfront, milestone and royalty data
- Comprehensive access to over 150 actual colorectal cancer deals entered into by the world?s biopharma companies since 2007
- Insight into key deal terms included in contracts, where disclosed
- Understand the key deal terms companies have agreed in deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
- $995: single-user
- $1,495: multi-user
- $2,995: single site license
- $4,975: global site license
An annual subscription to quarterly updates can be purchased for a small additional fee; ensuring you are kept up-to-date with the very latest colorectal cancer partnering deals. Quarterly updates available from $497.50.
A full explanation of license type definitions can be found here.
An additional $500 per copy will be added for full print and CD-ROM requests.
Source: http://www.currentpartnering.com/2012/02/22/colorectal-cancer-partnering-2007-2012/
barney frank rob gronkowski amityville horror kim richards andrew bogut robert hegyes mary louise parker
